Navigation Links
In Early Test, New Hepatitis C Drug Shows Promise
Date:4/21/2010

Medication offers hope for treatment with fewer side effects, experts say,,,,

WEDNESDAY, April 21 (HealthDay News) -- Researchers are reporting that a drug is showing promise in early testing as a possible new treatment for hepatitis C, a stubborn and potentially deadly liver ailment.

It's too early to tell if the drug actually works, and it will be years before it's ready to seek federal approval to be prescribed to patients. Still, the drug -- or others like it in development -- could add to the power of new drugs in the pipeline that are poised to cure many more people with hepatitis C, said Dr. Eugene R. Schiff, director of the University of Miami's Center for Liver Diseases.

The greater possibility of a cure and fewer side effects, in turn, will lead more people who think they have hepatitis C to "come out of the woodwork," said Schiff, who's familiar with the study findings. "They'll want to know if they're positive."

An estimated 4 million people in the United States have hepatitis C, but only about 1 million are thought to have been diagnosed. The disease, transmitted through infected blood, can lead to liver cancer, scarring of the liver, known as cirrhosis, and death.

Existing treatments can cure about half of the cases. As Schiff explained, people's genetic makeup has a lot to do with whether they respond to the treatment. Those with Asian heritage do better, whereas those with an African background do worse, he said.

And there's another potential problem with existing treatments. The side effects, particularly of the treatment component known as interferon, can be "pretty hard to deal with," said Nicholas A. Meanwell, a co-author of the study and a researcher with the Bristol-Myers Squibb pharmaceutical company.

The study, published online April 21 in Nature, examines an experimental drug designed to combat the hepatitis C virus. It appears to work by interfering with a protective coating around a part of the virus that's key to its ability to reproduce, Meanwell said.

In a phase 1 trial, the first of three types of studies that new drugs must go through, researchers gave doses of the drug to a small number of people.

The level of the virus in their bodies dropped significantly for several days. The main side effect was headache, Meanwell said.

At this point, it's not clear how much the drug might cost or how it would work with existing drugs. However, Meanwell said, it could become part of a combination treatment of several drugs.

Schiff, the University of Miami doctor, said other companies are pursuing similar drugs.

For now, much of the attention in the world of liver disease is on two drugs -- telaprevir and boceprevir -- that Schiff expects will become available within the next year and a half.

Combination treatments using these drugs will become the standard treatment for many people, he said, and boost cure rates into the range of 70 to 80 percent. The drugs now under development, like the one in the new study, could be added to the regimen, he said.

More information

The U.S. Centers for Disease Control and Prevention has more on hepatitis C.



SOURCES: Eugene R. Schiff, M.D., professor, medicine, and director, division of hepatology and Center for Liver Diseases, University of Miami Miller School of Medicine, Miami; Nicholas A. Meanwell, Ph.D., researcher, Bristol-Myers Squibb, Wallingford, Conn.; April 21, 2010, Nature, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Increased EGFR levels may be an early marker of breast cancer
2. Childhood obesity interventions must begin early, UCSF experts say
3. Childhood Obesity Interventions Must Begin Early, UCSF Experts Say
4. Case Western Reserve receives nearly $8M to help providers enable adoption of EHRs in Ohio
5. Early Detection May Prevent Preemie Vision Problems
6. 9-country study shows wide variations in how women with early breast cancer are treated
7. Yearly Chlamydia Screening May Be Ineffective for Some
8. Simple Memory Test May Detect Early Alzheimers
9. Chemicals in Beauty Products Tied to Early Puberty in Girls
10. Simple Test May Spot Early Lung Cancer
11. Childhood Cancer Survivors At Higher Odds of Early Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... ... opioid overdose deaths now claim the lives of 62 Americans each day.(1) Yet ... against drug manufacturers, distributors, pharmacies and prescribers by more than half.(2) Novus ...
(Date:4/24/2017)... ANGELES, CA (PRWEB) , ... April 24, 2017 , ... ... picture is worth a thousand words. The good news for single women is that ... for Attraction," which is available on April 25th. Joan's insight, personal experiences and sparkling ...
(Date:4/24/2017)... ... ... “Reflections of God’s Work”: an enlightening collection of life lessons leading each ... published author, Jerri Broglin, a survivor of great loss who gained insight on how ... for those searching for answers, as we are finding the answers that are so ...
(Date:4/24/2017)... NC and Seattle, WA (PRWEB) , ... April ... ... utilized by 75+ leading lifestyle brands, work wear distributors and International relief organizations ... they can carry. The company also offers lifestyle and work wear collections via ...
(Date:4/22/2017)... ... April 22, 2017 , ... Ecommerce sales have grown every year since ... $394.9 billion. The consequences of rapid innovation and growth are often neglected in ... it is every business and individual’s job to give something back to the planet ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Inc ., a digital health company focused on modernizing and ... $25 million in Series B funding led by Qiming US ... Seattle that is part of a broader family ... included participation from SR One , who led ZappRx,s ... Google Ventures). As part of the financing, Mark McDade ...
(Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
Breaking Medicine Technology: